Abstract
For several years there has been extensive debate concerning the value of bone marrow transplantation (BMT), allogeneic (allo-BMT) or autologous (A-BMT), in acute myelogenous leukemia (AML) patients in first remission (CR). Before starting a proper randomized phase III trial in order to reach a conclusion on the value of BMT in terms of disease-free survival (DFS), i.e., the time from the first CR until relapse or death in CR, and duration of survival (S), several authors have tried to compare the DFS of the patients who underwent BMT with those who received chemotherapy as post-remission treatment (non-BMT group)
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
